Phenazine

Phenazine

SCHEMBL9174820

CCOS(=O)(=O)O.c1ccc2nc3ccccc3nc2c1

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 3/20 0.41
GLA P06280 1/20 0.41
LMNA P02545 2/20 0.41
HSD17B10 Q99714 2/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
RXFP1 Q9HBX9 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
ALDH1A1 P00352 5/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HPGD P15428 2/20 0.39
TSHR P16473 1/20 0.39
NQO2 P16083 2/20 0.38
CYP2C9 P11712 1/20 0.38
HIF1A Q16665 1/20 0.38
TOP2A P11388 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenazine SCHEMBL1226523 1.00 POLB (0.42) POLBMAPTKDM4EGLALMNA
SCHEMBL10674809 0.86 ALDH1A1 (0.43) POLBMAPTKDM4ELMNAHSD17B10
SCHEMBL31578887 0.84 NQO2 (0.65) POLBMAPTKDM4ELMNAMEN1
Phenazine SCHEMBL28658053 0.83 MAPT (0.55) POLBMAPTKDM4ELMNAMEN1
Quinoline SCHEMBL28332577 0.83 ALDH1A1 (0.53) MAPTKDM4ELMNAHSD17B10MEN1
Phenazine SCHEMBL8936740 0.82 NQO2 (0.61) POLBMAPTKDM4ELMNAMEN1
SCHEMBL8585681 0.81 NQO2 (0.46) POLBMAPTKDM4ELMNAMEN1
SCHEMBL8585680 0.81 NQO2 (0.48) POLBMAPTKDM4EGLALMNA
Catechol SCHEMBL23541091 0.80 CA2 (0.42) POLBMAPTKDM4ELMNAHSD17B10
Phenazine SCHEMBL2873102 0.79 MAPT (0.50) POLBMAPTKDM4ELMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210246485-A1 HISTAMINE MEASUREMENT METHOD AND KIT KIKKOMAN CORPORATION (JP) 2021-08-12 US claimed
WO-2020040113-A1 HISTAMINE MEASUREMENT METHOD AND KIT キッコーマン株式会社 2020-02-27 WO claimed
US-12565672-B2 Sampling method and kit for histamine measurement KIKKOMAN CORPORATION (JP) 2026-03-03 US disclosed
EP-3842804-B1 SAMPLING METHOD AND KIT FOR HISTAMINE MEASUREMENT KIKKOMAN CORP (JP) 2025-01-22 EP disclosed
US-20210310042-A1 SAMPLING METHOD AND KIT FOR HISTAMINE MEASUREMENT KIKKOMAN CORPORATION (JP) 2021-10-07 US disclosed
US-20210246485-A1 HISTAMINE MEASUREMENT METHOD AND KIT KIKKOMAN CORPORATION (JP) 2021-08-12 US disclosed
EP-3842804-A1 SAMPLING METHOD AND KIT FOR HISTAMINE MEASUREMENT Kikkoman Corporation (JP) 2021-06-30 EP disclosed
WO-2020040116-A1 SAMPLING METHOD AND KIT FOR HISTAMINE MEASUREMENT キッコーマン株式会社 2020-02-27 WO disclosed
WO-2020040113-A1 HISTAMINE MEASUREMENT METHOD AND KIT キッコーマン株式会社 2020-02-27 WO disclosed
EP-0354441-B1 Method for the colorimetric determination of analyte using enzymatic oxydation BOEHRINGER MANNHEIM GMBH (DE) 1995-05-17 EP disclosed
EP-0354441-A2 Method for the colorimetric determination of analyte using enzymatic oxydation Roche Diagnostics GmbH (DE) 1990-02-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210246485-A1 HISTAMINE MEASUREMENT METHOD AND KIT HRH2, KIT, HRH3 POLB 1349/4885MAPT 4628/4885KDM4E 1108/4885
US-12565672-B2 Sampling method and kit for histamine measurement HNMT, CMA1, KIT POLB 3119/4885MAPT 3279/4885KDM4E 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.